Pharmaceutical intermediates
Revumenib Intermediates
12 pharmaceutical intermediates for Revumenib. Indication: Leukemia.
About Revumenib
- Originator
- Vitae Pharmaceuticals Inc
- Indication
- Leukemia
- Approved Date
- 11/15/2024
- NCE Patent
- 11/15/2029
- DS/DP
- 06/08/2037
Available intermediates
12 intermediates currently listed for Revumenib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-((4-(2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide | 2169920-03-8 | / | / |
| 4-methylbenzene-1-sulfonic acid [trans-4-ethylsulfonylaminocyclohexyl] methyl ester | 2169920-33-4 | / | / |
| N-[trans-4-(hydroxymethyl)cyclohexyl]ethane-1-sulfonamide | 2169920-32-3 | / | / |
| methyl trans-4-aminocyclohexanecarboxylate hydrochloride | 61367-07-5 | / | / |
| tert-butyl 2-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate | 2169922-99-8 | / | / |
| tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate | 896464-16-7 | / | / |
| 2-((4-chloropyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide | 2169923-04-8 | / | / |
| tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride | 1023301-84-9 | / | / |
| tert-butyl 4-cyano-4-(tosyloxymethyl)piperidine-1-carboxylate | 929302-00-1 | / | / |
| N-ethyl-5-fluoro-N-isopropyl-2-(pyrimidin-5-yloxy)benzamide | 2169923-02-6 | / | / |
| N-ethyl-5-fluoro-2-hydroxy-N-isopropylbenzamide | 1549490-65-4 | / | / |
| N-ethyl-5-fluoro-N-isopropyl-2-methoxybenzamide | 2654082-93-4 | / | / |
Other programs under R
Building toward Revumenib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →